Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FutForm

Financiado

Cerrado

Future Formulations Developing Future Pharmaceuticals Through Advanced Analysis...

Future Formulations Developing Future Pharmaceuticals Through Advanced Analysis and Intersectoral Exchange The estimated cost of getting a new medicine to market is now in excess of $2.6 billion, with an additional $300 million (approx.) typically being directed towards post market approval research and development activities (includin... ver más

31/03/2020

THE UNIVERSITY OF...

414K€

Presupuesto del proyecto: 414K€

Líder del proyecto

THE UNIVERSITY OF NOTTINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-31

MSCA-RISE-2015: Marie Skłodowska-Curie Research and...

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

THE UNIVERSITY OF NOTTINGHAM

297.00K€ | Lider

HY2CARE BV

54.00K€ | Participante

ABIEL

27.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DESARROLLO DE TECNOLOGÍAS AVANZADAS PARA EL D... DESARROLLO DE TECNOLOGÍAS AVANZADAS PARA EL DISEÑO DE FÁRMAC... 611K€ Cerrado

UNAB13-4E-1659 Sistema de cálculo intensivo y almacenamiento en red de alta... 82K€ Cerrado

IMPACT Innovative Modelling for Pharmacological Advances through Co... 1M€ Cerrado

PTQ-09-02-01379 Modelos farmacocinéticos y farmacodinámicos de predicción en... 28K€ Cerrado

PTQ-13-05861 Proyecto DynAppHTM. Aplicación de Nuevas Tecnologías Bioanal... 44K€ Cerrado

ORBITO Oral biopharmaceutics tools 25M€ Cerrado

Duración del proyecto: 53 meses Fecha Inicio: 2015-10-28
Fecha Fin: 2020-03-31

Líder del proyecto

THE UNIVERSITY OF NOTTINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 414K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The estimated cost of getting a new medicine to market is now in excess of $2.6 billion, with an additional $300 million (approx.) typically being directed towards post market approval research and development activities (including testing of new indications, new formulations and new dosage strengths and regimens) (Nature Reviews Drug Discovery 13, 877 (2014)). These costs have increased >145% since 2003, and reflect an increasingly complex process in which there remains a high chance of failure in the expensive later phases of development. With the aim of reducing the times and costs associated with medicine development, increasing attention has focused on the development of approaches to better predict and/or optimize the behaviour of actives and their formulations at an earlier stage of development. Recent research within the School of Pharmacy (University of Nottingham (UoN)) has focussed on the application of advanced surface analytical and biophysical tools to address this need. This proposal will build on this activity via an intersectoral researcher exchange program focussed on supporting future pharmaceutical formulations development. The principal objective of FutForm is to translate the advanced analytical approaches developed within UoN, so that they become embedded into industrial practice for the development of future pharmaceutical processes and therapies. This will be achieved through a collaborative programme of researcher secondments with three small-medium enterprise (SME) companies, each with early stage innovative technologies in areas of importance to the future pharmaceutical industry, namely; enzyme formulations for improved cell isolation (Abiel s.r.l; Italy), nanoparticle platform formulations for oral and topical drug delivery (Inovapotek, Pharmaceutical Research and Development Lda; Portugal) and hydrogel formulations for cell-delivery (Hy2Care b.v.; Netherlands).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores